Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Stock Market News for December 27, 2016
by Zacks Equity Research
Major U.S. benchmarks ended the last trading session ahead of Christmas holiday on a positive note as investors continued to cheer Trump's promises.
Ironwood, Allergan Report Positive Linzess IBS-C Study Data
by Zacks Equity Research
Ironwood (IRWD) and Allergan (AGN) report phase IIb study data on colonic release formulations of Linzess for the treatment of irritable bowel syndrome with constipation.
Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe
by Arpita Dutt
J&J (JNJ) and Actelion are back in the limelight with the companies in exclusive talks regarding a possible deal.
Allergan to Buy LifeCell to Boost Regenerative Medicine Suite
by Zacks Equity Research
Allergan plc (AGN) announced that it has signed a definitive agreement to acquire LifeCell, the regenerative medicine unit of Texas-based privately held company Acelity for $2.9 billion in cash.
Biogen Names Commercial Officer as New CEO, Shares Fall
by Zacks Equity Research
Biogen Inc. (BIIB) has appointed its present chief commercial officer (CCO), Michel Vounatsos, as the new chief executive officer (CEO), effective Jan 6, 2017.
Should Biotech Investors Worry About Donald Trump?
by Arpita Dutt
It looks like biotech investors may have heaved a sigh of relief a bit too early when Presidential election results were announced last month.
Teva Copaxone EU Label to Omit Pregnancy Contraindication
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU.
Here's Why Teva Pharmaceutical's (TEVA) Stock Is Down Today
by Ryan McQueeney
Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.
Amgen/Allergan File for EU Approval of Avastin Biosimilar
by Zacks Equity Research
Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
Company News for November 03, 2016
by Zacks Equity Research
Companies In The News are: GILD,AGN,CLX,EL
Your Two Minute Earnings Preview for Allergan (AGN) Stock
by Eric Dutram
It has been a tough run for Allergan thanks to broader sector woes which have punished companies across the industry. But, can AGN turn things around in its report later this week?
5 Healthcare Stocks Poised to Trump Q3 Earnings
by Zacks Equity Research
Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter.
Stock Market News for September 21, 2016
by Zacks Equity Research
Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today
Bayer Finally Buys Monsanto, Inflation Vanishes
by Mark Vickery
The agribusiness giant has agreed to be purchased by the German Big Pharma staple for $66 billion, and Import/Export prices swing to negative territory.
Stock Market News for August 09, 2016
by Zacks Equity Research
Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks
Stock Market News for June 16, 2016
by Zacks Equity Research
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
Stock Market News for May 10, 2016
by Zacks Equity Research
Benchmarks closed mixed on Monday after gains in healthcare stocks offset declines in energy stocks
Stock Market News for April 12, 2016
by Zacks Equity Research
Benchmarks closed in the red on Monday following losses in healthcare and consumer staples stocks.
Stock Market News for April 07, 2016
by Zacks Equity Research
Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks
Stock Market News for March 16, 2016
by Zacks Equity Research
Benchmarks ended mostly in the red following losses in healthcare and biotech stocks. Further, continuing decline in oil prices also weighed on key U.S. indexes
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
Valeant Pharma Autopsy: Counting the Lost Billions
by Kevin Cook
10 of the smartest investors in the world just lost sizable fortunes, in 2 months, on one stock.
Pharma Stock Outlook - July 2015
by Arpita Dutt
Mergers, acquisitions and deals continue to take center-stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions and licensing agreements are concerned, the trend continues this year as well.